August 01, 2014 8:28 PM ET

Capital Markets

Company Overview of Abingworth LLP

Company Overview

Abingworth LLP is a private equity and venture capital firm specializing in investments in all stages of development including early venture, mid venture, venture growth, and late-stage venture financing, growth equity, expansion capital, PIPE, VIPEs (venture investments in public equities) and acquisition financing. The firm also provides structured financing for recapitalizations, build-ups, and growth buyouts. It also seeks to invest in undervalued public companies. The firm invests in healthcare services and information technology with a focus on providers, payors, specialty services, software, and related services and on life sciences with a focus on specialty pharmaceuticals, life scie...

38 Jermyn Street

Princes House

5th Floor

London,  SW1Y 6DN

United Kingdom

Founded in 1973


44 20 7534 1500


44 20 7287 0480

Key Executives for Abingworth LLP

Managing Partner
Age: 61
Chief Financial Officer and Partner
Executive Partner and General Counsel
Special Partner
Age: 67
Compensation as of Fiscal Year 2014.

Abingworth LLP Key Developments

Abingworth LLP Promotes Ken Haas and Vin Miles to Partners

Abingworth LLP announced the promotions of Ken Haas and Vin Miles to Partners. They are both based in the US where they source and manage deals including early-stage and late-stage venture capital, venture growth and public market investments as well as VIPEs (Venture Investments in Public Equities). Ken Haas has spent 25 years in the management of both early-stage and public high technology and biotechnology companies. As part of the Abingworth team, Ken has led several investments including Clovis Oncology, Gynesonics and Intellikine. Before joining Abingworth, he was part of the founding management team at IntelliGenetics. Vin Miles has more than 30 years of management experience in the biotech industry. He is currently on the boards of Chiasma, Dicerna, Hydra BioSciences and Magellan Bioscience. Before joining Abingworth in 2007, he was Senior Vice President, Business Development, of the Abingworth portfolio company, Alnylam Pharmaceuticals. Previously, Vin was at Millennium Pharmaceuticals, where he held VP positions in business development, strategic planning and corporate communications.

Abingworth LLP Presents at BioEquity Europe 2014, May-21-2014 through May-22-2014

Abingworth LLP Presents at BioEquity Europe 2014, May-21-2014 through May-22-2014. Venue: Hilton Amsterdam Hotel, Amsterdam, Netherlands. Presentation Date(s): May-21-2014.

Abingworth LLP Presents at BioTrinity 2014 - European Biopartnering and Investment Conference, May-12-2014 through May-14-2014

Abingworth LLP Presents at BioTrinity 2014 - European Biopartnering and Investment Conference, May-12-2014 through May-14-2014. Venue: London, United Kingdom. Presentation Date & Speakers: May-14-2014, Timothy J. Haines, Partner.

Recent Private Companies Transactions

Private Placement
May 13, 2014
Proteon Therapeutics, Inc.
April 16, 2014
Zalicus Inc.
Private Placement
April 16, 2014
Wilson Therapeutics AB

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Abingworth LLP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at